For in-vitro research use only · Not for human consumption · Not medical advice
The Selective GH Secretagogue
Most growth hormone releasers also spike cortisol and hunger hormones. Ipamorelin is different — it triggers GH release without the side effects, making it the cleanest secretagogue researchers have found.
Molecular Weight
711.85 Da
CAS Number
170851-70-4
Amino Acids
5 residues
In Plain English
Think of your pituitary gland as a control panel with multiple buttons. One button releases growth hormone. Another releases cortisol (the stress hormone). Another triggers ghrelin (the hunger hormone). Older GH secretagogues — like GHRP-6 and GHRP-2 — press all the buttons at once. You get growth hormone, but you also get a flood of cortisol and an intense spike in appetite.
Ipamorelin is selective. It presses only the growth hormone button. Research shows it activates the GHS-R1a receptor (the ghrelin receptor) on pituitary cells to release GH, but it does so without significantly affecting ACTH or cortisol levels. This selectivity is what makes it so interesting to researchers.
It's a pentapeptide — just five amino acids long — which makes it one of the smallest and most elegant GH secretagogues. Despite its size, its binding specificity is remarkable. It fits the ghrelin receptor like a key in a lock, triggering the calcium signaling cascade that releases stored GH from somatotroph cells.
This clean profile is why researchers often pair Ipamorelin with CJC-1295. The two work through completely different receptors (GHS-R1a and GHRH-R), creating a dual-pathway amplification of GH release that neither compound achieves alone — all without cortisol contamination.
Plain English: Ipamorelin releases growth hormone from the pituitary without the cortisol spike, hunger surge, or other side effects that older GH secretagogues produce. It's the most selective compound in its class.
How It Works
Ipamorelin binds the Growth Hormone Secretagogue Receptor 1a with high specificity. Unlike GHRP-6, it doesn't significantly activate receptors that trigger cortisol (ACTH) or appetite (ghrelin) signaling — delivering GH release through a clean, isolated pathway.
When Ipamorelin binds its receptor, it triggers an intracellular calcium influx in pituitary somatotroph cells. This calcium wave is the signal that causes vesicles containing stored growth hormone to fuse with the cell membrane and release their contents.
Research consistently shows that Ipamorelin does not significantly elevate ACTH, cortisol, or prolactin levels — even at higher concentrations. This makes it uniquely clean among GH secretagogues, avoiding the stress-hormone cascade that undermines recovery.
Evidence
Selectivity Profile
Comparative studies between Ipamorelin and GHRP-6 demonstrated that Ipamorelin produces comparable GH elevation while showing no significant increase in ACTH or cortisol, even at doses 200 times the effective GH-releasing concentration.
Takeaway: Ipamorelin's selectivity isn't marginal — it's profound. Even at extreme concentrations, it doesn't trip the cortisol wire.
Bone Density
Research in animal models has shown Ipamorelin to increase bone mineral content and bone formation markers, consistent with GH's known anabolic effects on skeletal tissue. These findings suggest potential research applications in age-related bone loss.
Takeaway: GH's effects on bone are well-established, and Ipamorelin provides a clean way to study these pathways without cortisol interference.
GH Pulsing
Studies show Ipamorelin produces a dose-dependent GH response that follows natural pulsatile patterns. The pituitary's somatostatin feedback remains intact, meaning the body's "off switch" still works — preventing excess GH accumulation.
Takeaway: Ipamorelin respects the body's natural GH regulation — it amplifies the signal without overriding the safety mechanisms.
Sleep & Recovery
Since the largest natural GH pulse occurs during slow-wave sleep, Ipamorelin's ability to amplify GH release without cortisol elevation is particularly relevant. Cortisol disrupts sleep architecture — so a secretagogue that avoids it may support rather than impair restorative sleep.
Takeaway: Unlike older secretagogues that spike cortisol (a sleep disruptor), Ipamorelin's clean profile makes it compatible with sleep-optimized research protocols.
AminoVita Research Compound
$39.99
99%+ purity · Third-party tested · 5 mg
View ProductSubscribe & Save 10% — Free shipping on every order
Further Reading
Mechanism Deep Dive
How Ipamorelin achieves GH release through GHS-R1a without triggering cortisol, and why this clean profile changes the research landscape.
Wellness Science
How elevated cortisol fragments sleep architecture, suppresses GH pulsing, and creates a vicious cycle of poor recovery and metabolic decline.
FAQ
Selectivity means Ipamorelin triggers growth hormone release without significantly increasing other hormones like cortisol, ACTH, or prolactin. Older GH secretagogues like GHRP-6 activate multiple pathways simultaneously, causing unwanted cortisol and appetite spikes. Ipamorelin isolates the GH pathway.
All three release GH through the ghrelin receptor, but GHRP-6 causes intense hunger and significant cortisol elevation. GHRP-2 is less extreme but still raises cortisol. Ipamorelin achieves comparable GH release with neither side effect — it's a generational improvement in secretagogue design.
Cortisol is catabolic — it breaks down tissue, disrupts sleep, promotes fat storage, and suppresses immune function. If you're studying a compound in recovery-related research and repair, having it simultaneously spike cortisol is counterproductive. Ipamorelin avoids this contradiction entirely.
Not sure where to start? Browse compounds by research goal and find the right combination for your objectives.
Browse Catalog